[A20-43] Darolutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

Last updated 03.08.2020

Project no.:
A20-43

Commission:
Commission awarded on 30.04.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adults with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease

Result of dossier assessment:

Indication of considerable added benefit

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

03.08.2020

Darolutamide in prostate cancer: indication of considerable added benefit

Advantages in overall survival, symptoms and health-related quality of life

Project no. Title Status
A20-84 Darolutamide (prostate cancer) - Addendum to Commission A20-43 Commission completed

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.